Specify a stock or a cryptocurrency in the search bar to get a summary
ENZON PHARM (EZ1.SG)
ENZNEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey. Address: 20 Commerce Drive, Cranford, NJ, United States, 07016
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ENZN
Dividend Analytics ENZN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
-813 %Dividend History ENZN
Stock Valuation ENZN
Financials ENZN
Results | 2019 | Dynamics |